

30 January 2026

India | Equity Research | Results Update

Dabur India

Consumer Staples & Discretionary

Secular growth trend missing

Dabur's Q3FY26 performance is largely driven by the heavy lifting from particularly Hair Care and Oral Care segments. However, growth breadth remains limited, with several categories showing muted momentum and lacking meaningful market share gains, constraining overall volume traction. Moreover, Healthcare, a margin-accretive segment, has lacked strong growth, restricting any material earnings improvement. The company's three-year revenue CAGR of ~5% remains underwhelming vs. peers, underscoring the absence of a durable, demand-led growth cycle. With volume recovery still modest, growth increasingly appears dependent on price/mix and portfolio skew, which in a competitive environment, raises questions on sustainability. **HOLD**.

Management paints optimistic outlook for FY27

Dabur's Q3FY26 result was largely in line with our expectations. India FMCG (ex-Badshah) revenue/volume growing 6%/3% YoY (on a favourable base), impacted by transient headwinds in Oct'25 given liquidation of old MRP inventory post GST rate cuts and weak beverages sales. Sales growth was supported by strong growth in HPC, partly offset by weak performance in healthcare and beverage segments. International business performed well with broad-based growth across geographies, witnessing 7.5%/11.1% growth in CC/ INR in terms. Management targets high-single-digit to low-double-digits revenue growth (~2% price hike) in FY27 aided by GST benefits and an anticipated favourable weather; expects better profitability over last year as raw material prices turn favourable. We maintain our cautious stance on Dabur given its volatile quarterly performance. We await more consistent performance in HPC and health care portfolios, and recovery in beverage portfolio.

HPC growth strong, while beverage impacts F&B segment

Healthcare grew 2.7% YoY driven by Honey, Hajmola, and Honitus. Dabur Honey grew 10% YoY while Chyawanprash primary sales were flat impacted by excess channel inventory (secondary sales is good). Hajmola grew in high-single-digit led by good growth in candies, while Honitus witnessed strong double-digit growth aided by a favourable season. **HPC** segment grew 10.6% YoY driven by ~19% YoY growth in hair oils and ~10% YoY growth in toothpaste (gained market share). Herbal toothpaste market growth is ~500bps ahead of overall toothpaste market.

Financial Summary

| Y/E March (INR mn) | FY25A | FY26E | FY27E | FY28E |
|--------------------|----------|----------|----------|----------|
| Net Revenue | 1,25,631 | 1,31,609 | 1,44,230 | 1,58,189 |
| EBITDA | 23,163 | 24,553 | 27,193 | 30,163 |
| EBITDA Margin (%) | 18.4 | 18.7 | 18.9 | 19.1 |
| Net Profit | 17,676 | 18,611 | 20,995 | 23,651 |
| EPS (INR) | 10.0 | 10.5 | 11.9 | 13.4 |
| EPS % Chg YoY | (4.1) | 5.3 | 12.8 | 12.7 |
| P/E (x) | 51.0 | 48.4 | 42.9 | 38.1 |
| EV/EBITDA (x) | 38.1 | 35.9 | 32.0 | 28.4 |
| RoCE (%) | 12.3 | 12.5 | 13.1 | 13.7 |
| RoE (%) | 16.4 | 16.1 | 16.9 | 17.5 |

Manoj Menon

manoj.menon@icicisecurities.com
+91 22 6807 7209

Dhiraj Mistry

dhiraj.mistry@icicisecurities.com

Ashutosh Joytiraditya

ashutosh.joytiraditya@icicisecurities.com

Akshay Krishnan

akshay.krishnan@icicisecurities.com

Market Data

| | |
|---------------------|-----------|
| Market Cap (INR) | 905bn |
| Market Cap (USD) | 9,841mn |
| Bloomberg Code | DABUR IN |
| Reuters Code | DABU.BO |
| 52-week Range (INR) | 577 / 420 |
| Free Float (%) | 33.0 |
| ADTV-3M (mn) (USD) | 12.1 |

| Price Performance (%) | 3m | 6m | 12m |
|-----------------------|-----|-------|-------|
| Absolute | 0.5 | (1.5) | (1.5) |
| Relative to Sensex | 3.3 | (3.0) | (9.4) |

| ESG Score | 2024 | 2025 | Change |
|-------------|------|------|--------|
| ESG score | 75.7 | 77.3 | 1.6 |
| Environment | 68.1 | 68.7 | 0.6 |
| Social | 76.3 | 81.2 | 4.9 |
| Governance | 81.3 | 81.1 | (0.2) |

Note - Score ranges from 0 - 100 with a higher score indicating higher ESG disclosures.

Source: SES ESG, I-sec research

Previous Reports

31-10-2025: [Q2FY26 results review](#)

01-08-2025: [Q1FY26 results review](#)

Bleaches and facial kit portfolio grew well, while Odonil grew in mid-single-digit led by double-digit growth in gels and aerosol. Sanifresh grew in high-single-digit. Shampoo sales grew in mid-single-digit with market share gains. Foods and beverages (F&B) segment declined 1.1% YoY.

Foods portfolio grew 14% YoY driven by strong growth in coconut milk, edible oils and fats. Beverages segment growth was muted due to trade disruption on account of GST rate cuts and off-season quarter for drinks. Management remains positive on the beverages growth in the near term given reduced price differential between carbonates and juices (GST rate cut benefit) and upcoming summer season. It targets double-digit growth for the beverages portfolio in the near term.

Price hikes and prudent cost management drive profitability

Consol. gross margin expanded ~30bps YoY to 48.4% aided by calibrated price hikes. EBITDA margin expanded 31bps YoY to 20.6% driven by cost-saving initiatives; A&P spends as a percentage of sales were 6.7% vs. 6.8% last year. Recurring PAT grew 10.2% YoY.

Valuation and risks

We marginally tweak our estimates for FY26–28 and model revenue/EBITDA/PAT CAGRs of 8 / 9 / 10 (%) over FY25–28E. Maintain **HOLD** with an unchanged DCF-based target price of INR 500.

Key upside risk: Lower-than-expected competitive intensity. **Key downside risks:** Sustained weakness in consumption demand and slower-than-expected pick-up in rural demand.

Exhibit 1: Q3FY26 result overview (consolidated)

| INR mn | Q3FY26 | Q3FY25 | % Chg | Q2FY26 | % Chg | 9MFY26 | 9MFY25 | % Chg |
|-----------------------|---------------|---------------|-------------|---------------|-------------|----------------|---------------|------------|
| Total Income | 35,587 | 33,553 | 6.1 | 31,913 | 11.5 | 101,546 | 97,330 | 4.3 |
| Cost of Raw material | 18,369 | 17,428 | 5.4 | 16,135 | 13.8 | 52,537 | 50,258 | 4.5 |
| % of sales | 51.6 | 51.9 | -33 bps | 50.6 | 106 bps | 51.7 | 51.6 | 10 bps |
| Employees cost | 3,518 | 3,352 | 5.0 | 3,479 | 1.1 | 10,375 | 9,969 | 4.1 |
| % of net sales | 9.9 | 10.0 | -10 bps | 10.9 | -101 bps | 10.2 | 10.2 | -3 bps |
| A&P spends | 2,380 | 2,267 | 5.0 | 2,336 | 1.9 | 6,736 | 6,882 | (2.1) |
| % of net sales | 6.7 | 6.8 | -7 bps | 7.3 | -63 bps | 6.6 | 7.1 | -44 bps |
| Other expenditure | 3,978 | 3,686 | 7.9 | 4,083 | (2.6) | 11,999 | 11,326 | 5.9 |
| % of net sales | 11.2 | 11.0 | 19 bps | 12.8 | -162 bps | 11.8 | 11.6 | 18 bps |
| EBITDA | 7,341 | 6,819 | 7.7 | 5,881 | 24.8 | 19,900 | 18,895 | 5.3 |
| EBITDA margin% | 20.6 | 20.3 | 31 bps | 18.4 | 220 bps | 19.6 | 19.4 | 18 bps |
| Depreciation | 1,172 | 1,086 | 7.9 | 1,154 | 1.6 | 3,467 | 3,287 | 5.5 |
| Interest | 311 | 442 | (29.6) | 397 | (21.6) | 1,054 | 1,243 | (15.1) |
| Other Income | 1,406 | 1,280 | 9.8 | 1,401 | 0.4 | 4,247 | 4,090 | 3.9 |
| Share from Associates | (3) | 5 | (160.0) | (1) | 200.0 | (8) | 5 | (248.1) |
| PBT | 7,262 | 6,576 | 10.4 | 5,730 | 26.7 | 19,618 | 18,460 | 6.3 |
| Tax | 1,575 | 1,418 | 11.1 | 1,282 | 22.8 | 4,401 | 4,183 | 5.2 |
| Tax rate (%) | 21.7 | 21.6 | 13 bps | 22.4 | -69 bps | 22.4 | 22.7 | -23 bps |
| Recurring PAT | 5,687 | 5,158 | 10.2 | 4,448 | 27.8 | 15,217 | 14,277 | 6.6 |
| Extra ordinary items | (151) | - | | - | | (151) | - | |
| Minority Interest | (64) | (66) | | (78) | | (197) | (183) | |
| Reported PAT | 5,600 | 5,224 | 7.2 | 4,526 | 24 | 15,264 | 14,460 | 5.6 |
| EPS | 3.2 | 2.9 | 10.0 | 2.6 | 27 | 8.7 | 8.2 | 6.5 |


Source: I-Sec research, Company data

Exhibit 2: Q3FY26 result overview (standalone)

| INR mn | Q3FY26 | Q3FY25 | % Chg | Q2FY26 | % Chg | 9MFY26 | 9MFY25 | % Chg |
|----------------------|---------------|---------------|------------|---------------|-------------|---------------|---------------|------------|
| Total Income | 25,474 | 24,483 | 4.0 | 22,348 | 14.0 | 72,517 | 71,060 | 2.0 |
| Cost of Raw material | 13,556 | 13,270 | 2.2 | 11,797 | 14.9 | 39,142 | 38,511 | 1.6 |
| % of sales | 53.2 | 54.2 | -99 bps | 52.8 | 43 bps | 54.0 | 54.2 | -22 bps |
| Employees cost | 2,146 | 2,060 | 4.2 | 2,134 | 0.6 | 6,338 | 6,166 | 2.8 |
| % of net sales | 8.4 | 8.4 | 1 bps | 9.5 | -112 bps | 8.7 | 8.7 | 6 bps |
| A&P spends | 1,742 | 1,660 | 4.9 | 1,722 | 1.1 | 4,974 | 5,196 | (4.3) |
| % of net sales | 6.8 | 6.8 | 5 bps | 7.7 | -87 bps | 6.9 | 7.3 | -45 bps |
| Other expenditure | 2,477 | 2,267 | 9.3 | 2,455 | 0.9 | 7,417 | 6,960 | 6.6 |
| % of net sales | 9.7 | 9.3 | 47 bps | 11.0 | -126 bps | 10.2 | 9.8 | 43 bps |
| EBITDA | 5,553 | 5,226 | 6.3 | 4,240 | 31.0 | 14,645 | 14,227 | 2.9 |
| EBITDA margin% | 21.8 | 21.3 | 45 bps | 19.0 | 282 bps | 20.2 | 20.0 | 17 bps |
| Depreciation | 663 | 638 | 3.9 | 641 | 3.3 | 1,936 | 1,877 | 3.1 |
| Interest | 222 | 283 | (21.8) | 196 | 13.1 | 590 | 767 | (23.0) |
| Other Income | 1,079 | 1,053 | 2.4 | 1,065 | 1.3 | 3,302 | 3,334 | (0.9) |
| PBT | 5,747 | 5,358 | 7.3 | 4,467 | 28.6 | 15,421 | 14,917 | 3.4 |
| Tax | 1,203 | 1,177 | 2.2 | 981 | 22.6 | 3,316 | 3,390 | -2.2 |
| Tax rate (%) | 20.9 | 22.0 | -104 bps | 22.0 | -102 bps | 21.5 | 22.7 | -122 bps |
| Recurring PAT | 4,545 | 4,181 | 8.7 | 3,487 | 30.3 | 12,105 | 11,527 | 5.0 |
| Extra ordinary items | (151) | - | - | - | - | (151) | - | - |
| Reported PAT | 4,394 | 4,181 | 5.1 | 3,487 | 26.0 | 11,955 | 11,527 | 3.7 |


Source: I-Sec research, Company data

Exhibit 3: Domestic volume growth trend




Source: Company data, I-Sec research

Exhibit 4: Revenue growth trend




Source: I-Sec research, Company data


Exhibit 5: Gross margin and EBITDA margin trend



Source: I-Sec research, Company data

Exhibit 6: EBITDA and EBITDA growth trend

Source: Bloomberg, I-Sec research

Exhibit 7: PAT and PAT growth trend

Source: Bloomberg, I-Sec research

Exhibit 8: Shareholding pattern

| % | Jun'25 | Sep'25 | Dec'25 |
|-------------------------|--------|--------|--------|
| Promoters | 66.2 | 66.2 | 66.2 |
| Institutional investors | 28.1 | 28.1 | 28.5 |
| MFs and others | 8.4 | 9.2 | 7.3 |
| FIs/Banks | 7.8 | 8.0 | 11.1 |
| FIIIs | 11.9 | 10.9 | 10.1 |
| Others | 5.7 | 5.7 | 5.3 |

Source: Bloomberg, I-Sec research

Exhibit 9: Price chart

Source: Bloomberg, I-Sec research

Financial Summary

Exhibit 10: Profit & Loss

(INR mn, year ending March)

| | FY25A | FY26E | FY27E | FY28E |
|--|-----------------|-----------------|-----------------|-----------------|
| Net Sales | 1,25,631 | 1,31,609 | 1,44,230 | 1,58,189 |
| Operating Expenses | 1,02,468 | 1,07,055 | 1,17,038 | 1,28,025 |
| EBITDA | 23,163 | 24,553 | 27,193 | 30,163 |
| EBITDA Margin (%) | 18.4 | 18.7 | 18.9 | 19.1 |
| Depreciation & Amortization | 4,456 | 4,659 | 4,795 | 4,931 |
| EBIT | 18,707 | 19,894 | 22,397 | 25,232 |
| Interest expenditure | 1,635 | 1,390 | 1,251 | 1,126 |
| Other Non-operating Income | 5,501 | 5,666 | 6,119 | 6,609 |
| Recurring PBT | 22,573 | 24,170 | 27,266 | 30,715 |
| Profit / (Loss) from Associates | 6 | - | - | - |
| Less: Taxes | 5,175 | 5,559 | 6,271 | 7,064 |
| PAT | 17,399 | 18,611 | 20,995 | 23,651 |
| Less: Minority Interest | 272 | - | - | - |
| Extraordinaries (Net) | - | - | - | - |
| Net Income (Reported) | 17,676 | 18,611 | 20,995 | 23,651 |
| Net Income (Adjusted) | 17,676 | 18,611 | 20,995 | 23,651 |

Source Company data, I-Sec research

Exhibit 11: Balance sheet

(INR mn, year ending March)

| | FY25A | FY26E | FY27E | FY28E |
|--|-----------------|-----------------|-----------------|-----------------|
| Total Current Assets | 65,325 | 65,911 | 81,212 | 99,621 |
| of which cash & cash eqv. | 5,780 | 5,478 | 16,986 | 31,199 |
| Total Current Liabilities & Provisions | 38,540 | 27,843 | 30,513 | 33,466 |
| Net Current Assets | 26,784 | 38,068 | 50,699 | 66,155 |
| Investments | 53,724 | 53,724 | 53,724 | 53,724 |
| Net Fixed Assets | 40,002 | 37,342 | 34,547 | 31,615 |
| ROU Assets | - | - | - | - |
| Capital Work-in-Progress | 1,664 | 1,664 | 1,664 | 1,664 |
| Total Intangible Assets | - | - | - | - |
| Long Term Loans & Advances | 214 | 64 | 64 | 64 |
| Deferred Tax assets | 25 | 25 | 25 | 25 |
| Total Assets | 1,23,783 | 1,31,206 | 1,41,042 | 1,53,566 |
| Liabilities | | | | |
| Borrowings | 7,301 | 7,301 | 7,301 | 7,301 |
| Deferred Tax Liability | 1,443 | 1,443 | 1,443 | 1,443 |
| Provisions | 715 | 786 | 865 | 951 |
| Other Liabilities | 2,222 | 2,444 | 2,688 | 2,957 |
| Equity Share Capital | 1,772 | 1,772 | 1,772 | 1,772 |
| Reserves & Surplus | 1,06,235 | 1,13,364 | 1,22,877 | 1,35,046 |
| Total Net Worth | 1,08,007 | 1,15,136 | 1,24,649 | 1,36,818 |
| Minority Interest | 4,096 | 4,096 | 4,096 | 4,096 |
| Total Liabilities | 1,23,783 | 1,31,206 | 1,41,042 | 1,53,566 |

Source Company data, I-Sec research

Exhibit 12: Quarterly trend

(INR mn, year ending March)

| | Mar 25 | Jun 25 | Sep 25 | Dec 25 |
|---------------------|--------|--------|--------|--------|
| Net Sales | 28,301 | 34,046 | 31,913 | 35,587 |
| % growth (YOY) | 0.6 | 1.7 | 5.4 | 6.1 |
| EBITDA | 4,269 | 6,678 | 5,881 | 7,341 |
| Margin % | 15.1 | 19.6 | 18.4 | 20.6 |
| Other Income | 1,412 | 1,440 | 1,401 | 1,406 |
| Extraordinaries | - | - | - | (151) |
| Adjusted Net Profit | 3,201 | 5,139 | 4,526 | 5,750 |

Source Company data, I-Sec research

Exhibit 13: Cashflow statement

(INR mn, year ending March)

| | FY25A | FY26E | FY27E | FY28E |
|--|----------------|---------------|---------------|---------------|
| Operating Cashflow | 24,558 | 14,569 | 26,240 | 28,821 |
| Working Capital Changes | 790 | (10,091) | (800) | (887) |
| Capital Commitments | (5,576) | (2,000) | (2,000) | (2,000) |
| Free Cashflow | 18,982 | 12,569 | 24,240 | 26,821 |
| Other investing cashflow | (5,346) | - | - | - |
| Cashflow from Investing Activities | (10,922) | (2,000) | (2,000) | (2,000) |
| Issue of Share Capital | 0 | - | - | - |
| Interest Cost | (1,635) | (1,390) | (1,251) | (1,126) |
| Inc (Dec) in Borrowings | (4,280) | - | - | - |
| Dividend paid | (11,482) | (11,482) | (11,482) | (11,482) |
| Others | 2,877 | - | - | - |
| Cash flow from Financing Activities | (14,519) | (12,871) | (12,732) | (12,607) |
| Chg. in Cash & Bank balance | (884) | (302) | 11,508 | 14,213 |
| Closing cash & balance | 5,780 | 5,478 | 16,986 | 31,199 |

Source Company data, I-Sec research

Exhibit 14: Key ratios

(Year ending March)

| | FY25A | FY26E | FY27E | FY28E |
|-----------------------------|-------|-------|-------|-------|
| Per Share Data (INR) | | | | |
| Reported EPS | 10.0 | 10.5 | 11.9 | 13.4 |
| Adjusted EPS (Diluted) | 10.0 | 10.5 | 11.9 | 13.4 |
| Cash EPS | 12.5 | 13.2 | 14.6 | 16.2 |
| Dividend per share (DPS) | 6.5 | 6.5 | 6.5 | 6.5 |
| Book Value per share (BV) | 61.1 | 65.2 | 70.6 | 77.5 |
| Dividend Payout (%) | 65.0 | 61.7 | 54.7 | 48.5 |
| Growth (%) | | | | |
| Net Sales | 1.3 | 4.8 | 9.6 | 9.7 |
| EBITDA | (3.5) | 6.0 | 10.7 | 10.9 |
| EPS (INR) | (4.1) | 5.3 | 12.8 | 12.7 |
| Valuation Ratios (x) | | | | |
| P/E | 51.0 | 48.4 | 42.9 | 38.1 |
| P/CEPS | 40.7 | 38.7 | 35.0 | 31.5 |
| P/BV | 8.3 | 7.8 | 7.2 | 6.6 |
| EV / EBITDA | 38.1 | 35.9 | 32.0 | 28.4 |
| P / Sales | 7.2 | 6.9 | 6.3 | 5.7 |
| Dividend Yield (%) | 1.3 | 1.3 | 1.3 | 1.3 |
| Operating Ratios | | | | |
| Gross Profit Margins (%) | 48.0 | 48.1 | 48.3 | 48.5 |
| EBITDA Margins (%) | 18.4 | 18.7 | 18.9 | 19.1 |
| Effective Tax Rate (%) | 22.9 | 23.0 | 23.0 | 23.0 |
| Net Profit Margins (%) | 14.1 | 14.1 | 14.6 | 15.0 |
| Net Debt / Equity (x) | (0.2) | (0.2) | (0.2) | (0.3) |
| Net Debt / EBITDA (x) | (0.8) | (0.8) | (1.1) | (1.5) |
| Fixed Asset Turnover (x) | 1.9 | 1.9 | 2.0 | 2.2 |
| Working Capital Days | 61 | 92 | 89 | 84 |
| Inventory Turnover Days | 67 | 56 | 58 | 58 |
| Receivables Days | 26 | 36 | 37 | 37 |
| Payables Days | 83 | 61 | 62 | 62 |
| Profitability Ratios | | | | |
| RoCE (%) | 12.3 | 12.5 | 13.1 | 13.7 |
| RoE (%) | 16.4 | 16.1 | 16.9 | 17.5 |
| RoIC (%) | 37.1 | 35.8 | 37.9 | 44.7 |

Source Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com and Kadambari_balachandran@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We Manoj Menon, MBA, CMA; Dhiraj Mistry, CMA; Ashutosh Joytiraditya, MBA; Akshay Krishnan, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report.

SEBI Guidelines for Research Analyst (RA) requires all RAs to disclose terms and conditions pertaining to Research Services to all clients. Please go through the "Mandatory terms and conditions" and "Most Important Terms and Conditions. ([Link](#))

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, **E-mail Address** : complianceofficer@icicisecurities.com

For any queries or grievances: [Mr. Jeetu Jawrani](#) Email address: headservicequality@icicidirect.com Contact Number: 18601231122
